Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Rioth

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Current Treatment Options in Oncology|August 7, 2014
Immune checkpoint inhibitors in NSCLCDouglas B Johnson, Matthew J Rioth, Leora Horn
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Advances in website information resources to aid in clinical practiceMatthew J Rioth, Travis J Osterman, Jeremy L Warner
Journal of the American Academy of Dermatology|January 18, 2019
Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatmentMakenzie L Hawkins, Matthew J Rioth, Megan M Eguchi, et al.
Journal of the American Medical Informatics Association : JAMIA|March 31, 2016
Pragmatic precision oncology: the secondary uses of clinical tumor molecular profilingMatthew J Rioth, Ramya Thota, David B Staggs, et al.
Journal of Oncology Practice|January 28, 2016
Implementing and Improving Automated Electronic Tumor Molecular ProfilingMatthew J Rioth, David B Staggs, Lauren Hackett, et al.
Cancer Cell|May 6, 2008
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growthSandra Ryeom, Kwan-Hyuck Baek, Matthew J Rioth, et al.
Current Biology : CB|January 1, 2008
TORC1 is essential for NF1-associated malignanciesCory M Johannessen, Bryan W Johnson, Sybil M Genther Williams, et al.
Journal of the American Medical Informatics Association : JAMIA|March 29, 2016
SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of careJeremy L Warner, Matthew J Rioth, Kenneth D Mandl, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2006
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switchSylvie Giuriato, Sandra Ryeom, Alice C Fan, et al.
Cancers|August 23, 2020
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal MelanomaMerve Hasanov, Matthew J Rioth, Kari Kendra, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Treatment Options in Oncology|August 7, 2014
Immune checkpoint inhibitors in NSCLCDouglas B Johnson, Matthew J Rioth, Leora Horn
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Advances in website information resources to aid in clinical practiceMatthew J Rioth, Travis J Osterman, Jeremy L Warner
Journal of the American Academy of Dermatology|January 18, 2019
Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatmentMakenzie L Hawkins, Matthew J Rioth, Megan M Eguchi, et al.
Journal of the American Medical Informatics Association : JAMIA|March 31, 2016
Pragmatic precision oncology: the secondary uses of clinical tumor molecular profilingMatthew J Rioth, Ramya Thota, David B Staggs, et al.
Journal of Oncology Practice|January 28, 2016
Implementing and Improving Automated Electronic Tumor Molecular ProfilingMatthew J Rioth, David B Staggs, Lauren Hackett, et al.
Cancer Cell|May 6, 2008
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growthSandra Ryeom, Kwan-Hyuck Baek, Matthew J Rioth, et al.
Current Biology : CB|January 1, 2008
TORC1 is essential for NF1-associated malignanciesCory M Johannessen, Bryan W Johnson, Sybil M Genther Williams, et al.
Journal of the American Medical Informatics Association : JAMIA|March 29, 2016
SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of careJeremy L Warner, Matthew J Rioth, Kenneth D Mandl, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2006
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switchSylvie Giuriato, Sandra Ryeom, Alice C Fan, et al.
Cancers|August 23, 2020
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal MelanomaMerve Hasanov, Matthew J Rioth, Kari Kendra, et al.
Pageof 2